Document Detail


The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagitis.
MedLine Citation:
PMID:  1420752     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The combination of a histamine H2-receptor antagonist and a muscarinic receptor antagonist has been reported to result in greater suppression of intragastric acidity than either agent alone. The present randomized, double-blind, multicentre trial compared the effects of the oral combination of 150 mg ranitidine b.d. plus 50 mg pirenzepine b.d. with 150 mg ranitidine b.d. plus placebo pirenzepine b.d. in the treatment of patients with reflux oesophagitis. All 157 patients had symptoms of gastro-oesophageal reflux with endoscopically confirmed oesophageal erosions (Savary and Miller grades I-III). After four weeks of treatment, healing rates were 32/75 (43%) in the combined treatment group and 34/76 (45%) in the group receiving ranitidine alone. After eight weeks, the cumulative healing rates had increased to 48/72 (67%) and 51/75 (68%), respectively. More patients receiving ranitidine plus pirenzepine had complete relief of day- and night-time heartburn after four weeks compared with those receiving ranitidine alone (day: 59% vs. 38%, P = 0.02; night: 69% vs. 52%, P = 0.04). After eight weeks, symptom relief was comparable in both groups. Clinical adverse effects were reported by nine patients receiving ranitidine and by 19 patients receiving the combination. It is concluded that combining ranitidine with pirenzepine does not aid the healing of reflux oesophagitis but does improve symptom relief at four weeks.
Authors:
W Londong; J Phillips; N J Johnson; J R Wood
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  6     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  1992 Oct 
Date Detail:
Created Date:  1992-12-18     Completed Date:  1992-12-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  609-18     Citation Subset:  IM    
Affiliation:
2nd Medical Department, Krankenhaus am Urban, Berlin, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Aged
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Esophagitis, Peptic / drug therapy*
Female
Humans
Male
Middle Aged
Pirenzepine / adverse effects,  therapeutic use*
Ranitidine / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
28797-61-7/Pirenzepine; 66357-35-5/Ranitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophag...
Next Document:  Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease.